Preneoplastic and Neoplastic Small Lymphocytic Proliferations

“A life not lived for others is not a life.” –Mother Teresa

By SYED ALI ABUTALIB, MD, AND L. JEFFREY MEDEIROS, MD
November 25, 2025

Full Article Summary Notecard

1. CLL and SLL are B-cell lymphoproliferative disorders. 2. Diagnostic differentiation based on B-cell counts. 3. Key biomarkers include TP53 mutations. 4. MBL serves as a precursor to CLL/SLL. 5. Risk of Richter transformation in CLL/SLL patients. 6. IGHV mutation status impacts treatment decisions. 7. Comprehensive molecular assessments guide therapy planning.

Dec

Today In Oncology

Preneoplastic and Neoplastic Small Lymphocytic Proliferations

“A life not lived for others is not a life.” –Mother Teresa

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL

Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma